
Arie Pieter Kappetein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8878092/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term survival after coronary bypass surgery with multiple versus single arterial grafts. European Journal of Cardio-thoracic Surgery, 2022, 61, 925-933.	0.6	19
2	Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease. European Heart Journal, 2022, 43, 1334-1344.	1.0	17
3	Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization. European Journal of Preventive Cardiology, 2022, 29, 312-320.	0.8	6
4	10-Year All-Cause Mortality Following Percutaneous or Surgical Revascularization inÂPatientsÂWithÂHeavyÂCalcification. JACC: Cardiovascular Interventions, 2022, 15, 193-204.	1.1	23
5	Geographical variations in left main coronary artery revascularisation: a prespecified analysis of the EXCEL trial. EuroIntervention, 2022, 17, 1081-1090.	1.4	2
6	Endoscopic vs Open Vein Harvest in Drug-Eluting Stents or Bypass Surgery for Left Main Disease Trial. Annals of Thoracic Surgery, 2022, , .	0.7	0
7	Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial. EuroIntervention, 2022, 17, 1477-1487.	1.4	6
8	Mortality after multivessel revascularisation involving the proximal left anterior descending artery. Heart, 2022, 108, 1784-1791.	1.2	7
9	Impact of lesion preparation strategies on outcomes of left main <scp>PCI</scp> : The <scp>EXCEL</scp> trial. Catheterization and Cardiovascular Interventions, 2021, 98, 24-32.	0.7	7
10	Essential information on surgical heart valve characteristics for optimal valve prosthesis selection: Expert consensus document from the European Association for Cardio-Thoracic Surgery (EACTS)–The Society of Thoracic Surgeons (STS)–American Association for Thoracic Surgery (AATS) Valve Labelling Task Force. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 545-558.	0.4	3
11	Essential Information on Surgical Heart Valve Characteristics for Optimal Valve Prosthesis Selection: Expert Consensus Document From the European Association for Cardio-Thoracic Surgery (EACTS)–The Society of Thoracic Surgeons (STS)–American Association for Thoracic Surgery (AATS) Valve Labelling Task Force. Annals of Thoracic Surgery, 2021, 111, 314-326.	0.7	3
12	Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions. Journal of the American College of Cardiology, 2021, 77, 529-540.	1.2	17
13	Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 66-75.e4.	0.4	8
14	Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study. Clinical Research in Cardiology, 2021, 110, 1543-1553.	1.5	4
15	Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. Clinical Research in Cardiology, 2021, 110, 1083-1095.	1.5	10
16	Outpatient Versus Inpatient Percutaneous Coronary Intervention in Patients With Left Main Disease (from the EXCEL Trial). American Journal of Cardiology, 2021, 143, 21-28.	0.7	0
17	White blood cell count and clinical outcomes after left main coronary artery revascularization. Coronary Artery Disease, 2021, Publish Ahead of Print, 45-51.	0.3	0
18	Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease. Coronary Artery Disease, 2021. Publish Ahead of Print, 37-44	0.3	1

#	Article	IF	CITATIONS
19	Impact of stent length and diameter on 10â€year mortality in the <scp>SYNTAXES</scp> trial. Catheterization and Cardiovascular Interventions, 2021, 98, E379-E387.	0.7	10
20	Impact of the CABG SYNTAX score on all-cause death at 10 years: a SYNTAX Extended Survival (SYNTAXES) substudy. EuroIntervention, 2021, 17, 75-77.	1.4	3
21	10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease. Journal of the American College of Cardiology, 2021, 77, 2761-2773.	1.2	32
22	Impact of Body Composition Indices on Ten-year Mortality After Revascularization of Complex Coronary Artery Disease (From the Syntax Extended Survival Trial). American Journal of Cardiology, 2021, 151, 30-38.	0.7	6
23	Transit time flow measurement of coronary bypass grafts before and after protamine administration. Journal of Cardiothoracic Surgery, 2021, 16, 195.	0.4	4
24	Impact of Optimal Medical Therapy on 10-Year Mortality After CoronaryÂRevascularization. Journal of the American College of Cardiology, 2021, 78, 27-38.	1.2	41
25	Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study. Circulation, 2021, 144, 96-109.	1.6	41
26	Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease. Clinical Research in Cardiology, 2021, 110, 1680-1691.	1.5	4
27	The Clinical Implications of Body Surface Area as a Poor Proxy for Cardiac Output. Structural Heart, 2021, 5, 582-587.	0.2	11
28	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. European Heart Journal, 2021, 43, 56-67.	1.0	23
29	Impact of major infections on 10-year mortality after revascularization in patients with complex coronary artery disease. International Journal of Cardiology, 2021, 341, 9-12.	0.8	1
30	Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet, The, 2021, 398, 2247-2257.	6.3	115
31	Sutureless versus Stented Bioprostheses for Aortic Valve Replacement: The Randomized PERSIST-AVR Study Design. Thoracic and Cardiovascular Surgeon, 2020, 68, 114-123.	0.4	22
32	Intraoperative transit-time flow measurement and high-frequency ultrasound assessment in coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 1283-1292.e2.	0.4	41
33	Sex Differences in All-Cause Mortality in the Decade Following Complex CoronaryÂRevascularization. Journal of the American College of Cardiology, 2020, 76, 889-899.	1.2	30
34	Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. Lancet, The, 2020, 396, 1399-1412.	6.3	120
35	Impact of Peri-Procedural MyocardialÂInfarction on Outcomes AfterÂRevascularization. Journal of the American College of Cardiology, 2020, 76, 1622-1639.	1.2	73
36	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. Journal of the American College of Cardiology, 2020, 76, 1609-1621.	1.2	75

#	Article	IF	CITATIONS
37	Natural History of Asymptomatic Severe Aortic Stenosis and the Association of Early Intervention With Outcomes. JAMA Cardiology, 2020, 5, 1102.	3.0	34
38	Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial. JACC: Cardiovascular Interventions, 2020, 13, 323-331.	1.1	19
39	Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial. European Journal of Heart Failure, 2020, 22, 871-879.	2.9	27
40	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease. JACC: Cardiovascular Interventions, 2020, 13, 375-387.	1.1	55
41	Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting According to Smoking Status. American Journal of Cardiology, 2020, 127, 16-24.	0.7	4
42	The fallacy of indexed effective orifice area charts to predict prosthesis–patient mismatch after prosthesis implantation. European Heart Journal Cardiovascular Imaging, 2020, 21, 1116-1122.	0.5	16
43	Considerations for an optimal definition of procedural myocardial infarction. European Heart Journal, 2020, 41, 1704-1705.	1.0	7
44	Computed Tomography Annular Dimensions: A Novel Method to Compare Prosthetic Valve Hemodynamics. Annals of Thoracic Surgery, 2020, 110, 1502-1510.	0.7	1
45	Heart Team decision making and long-term outcomes for 1000 consecutive cases of coronary artery disease. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 206-213.	0.5	21
46	Off-Pump Versus On-Pump Bypass Surgery for Left Main Coronary ArteryÂDisease. Journal of the American College of Cardiology, 2019, 74, 729-740.	1.2	28
47	Long-Term Survival After SurgicalÂAorticÂValve Replacement. Journal of the American College of Cardiology, 2019, 74, 34-35.	1.2	1
48	Impact of non-respect of SYNTAX score II recommendation for surgery in patients with left main coronary artery disease treated by percutaneous coronary intervention: an EXCEL substudy. European Journal of Cardio-thoracic Surgery, 2019, 57, 676-683.	0.6	10
49	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet, The, 2019, 394, 1325-1334.	6.3	406
50	Left Main Coronary Artery Disease Revascularization According to the SYNTAX Score. Circulation: Cardiovascular Interventions, 2019, 12, e008007.	1.4	15
51	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. New England Journal of Medicine, 2019, 381, 1820-1830.	13.9	523
52	Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery. JAMA Cardiology, 2019, 4, 810.	3.0	12
53	Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial. American Heart Journal, 2019, 214, 9-17.	1.2	9
54	Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery forÂLeftÂMainÂDisease. Journal of the American College of Cardiology, 2019, 73, 1877-1886.	1.2	33

#	Article	IF	CITATIONS
55	Improving coronary artery bypass grafting: a systematic review and meta-analysis on the impact of adopting transit-time flow measurement. European Journal of Cardio-thoracic Surgery, 2019, 56, 654-663.	0.6	43
56	Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. European Heart Journal, 2019, 40, 1930-1941.	1.0	65
57	Bypass Surgery or Stenting for LeftÂMainÂCoronary Artery Disease in PatientsÂWith Diabetes. Journal of the American College of Cardiology, 2019, 73, 1616-1628.	1.2	60
58	Computed Tomography–Based Indexed Aortic Annulus Size to Predict Prosthesis-Patient Mismatch. Circulation: Cardiovascular Interventions, 2019, 12, e007396.	1.4	9
59	Life-long clinical outcome after the first myocardial revascularization procedures: 40-year follow-up after coronary artery bypass grafting and percutaneous coronary intervention in Rotterdam. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 852-859.	0.5	6
60	Outcomes of patients with and without baseline lipid-lowering therapy undergoing revascularization for left main coronary artery disease. Coronary Artery Disease, 2019, 30, 143-149.	0.3	1
61	Outcomes following surgical revascularization with single versus bilateral internal thoracic arterial grafts in patients with left main coronary artery disease undergoing coronary artery bypass grafting: insights from the EXCEL trialâ€. European Journal of Cardio-thoracic Surgery, 2019, 55, 501-510.	0.6	18
62	Impact of chronic obstructive pulmonary disease on prognosis after percutaneous coronary intervention and bypass surgery for left main coronary artery disease: an analysis from the EXCEL trial. European Journal of Cardio-thoracic Surgery, 2019, 55, 1144-1151.	0.6	6
63	C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial. American Heart Journal, 2019, 210, 49-57.	1.2	13
64	Causes of death in intermediate-risk patients: The Randomized Surgical Replacement and Transcatheter Aortic Valve Implantation Trial. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 718-728.e3.	0.4	16
65	Does an occluded RCA affect prognosis in patients undergoing PCI or CABG for left main coronary artery disease? Analysis from the EXCEL trial. EuroIntervention, 2019, 15, e531-e538.	1.4	1
66	Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet, The, 2018, 391, 939-948.	6.3	506
67	B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease. Circulation, 2018, 138, 469-478.	1.6	25
68	Compliance With Guideline-Directed Medical Therapy in Contemporary CoronaryÂRevascularization Trials. Journal of the American College of Cardiology, 2018, 71, 591-602.	1.2	92
69	New-Onset Atrial Fibrillation After PCIÂorÂCABGÂforÂLeft Main Disease. Journal of the American College of Cardiology, 2018, 71, 739-748.	1.2	94
70	Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. Circulation, 2018, 137, 388-399.	1.6	350
71	Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. European Heart Journal, 2018, 39, 2635-2642.	1.0	234
72	A case-vignette based assessment of patient's perspective on coronary revascularization strategies, the OPINION study. Journal of Cardiology, 2018, 72, 149-154.	0.8	6

#	Article	IF	CITATIONS
73	Long-term outlook for transcatheter aortic valve replacement. Trends in Cardiovascular Medicine, 2018, 28, 174-183.	2.3	14
74	Recognition, assessment and management of the mechanical complications of acute myocardial infarction. Heart, 2018, 104, 1216-1223.	1.2	30
75	Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With PriorÂCerebrovascular Disease. JACC: Cardiovascular Interventions, 2018, 11, 2441-2450.	1.1	6
76	Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e007007.	1.4	45
77	Neurological Complications AfterÂTranscatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients. Journal of the American College of Cardiology, 2018, 72, 2109-2119.	1.2	27
78	Interpretation of results of pooled analysis of individual patient data – Authors' reply. Lancet, The, 2018, 392, 818.	6.3	7
79	One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1368-1377.e5.	0.4	33
80	Outcomes After Left Main Percutaneous Coronary Intervention Versus CoronaryÂArtery Bypass Grafting According to Lesion Site. JACC: Cardiovascular Interventions, 2018, 11, 1224-1233.	1.1	38
81	Outcomes After Coronary Stenting or Bypass Surgery for Men and Women With Unprotected Left Main Disease. JACC: Cardiovascular Interventions, 2018, 11, 1234-1243.	1.1	58
82	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2018, 72, 754-765.	1.2	59
83	Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2018, 72, 386-398.	1.2	89
84	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation, 2018, 137, 2635-2650.	1.6	435
85	Reply to Gasz. European Journal of Cardio-thoracic Surgery, 2018, 54, 196-197.	0.6	1
86	One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. EuroIntervention, 2018, 14, 877-883.	1.4	59
87	Mechanical Complications of Acute Myocardial Infarction. , 2018, , 341-357.		0
88	Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. Journal of the American College of Cardiology, 2017, 69, 2039-2050.	1.2	63
89	Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesisâ€. European Journal of Cardio-thoracic Surgery, 2017, 52, 425-431.	0.6	33
90	Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2017, 52, 14-25.	0.6	106

#	Article	IF	CITATIONS
91	Mechanical versus bioprosthetic aortic valve replacement. European Heart Journal, 2017, 38, 2183-2191.	1.0	248
92	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2017, 52, 206-217.	0.6	39
93	Influence of practice patterns on outcome among countries enrolled in the SYNTAX trial: 5-year results between percutaneous coronary intervention and coronary artery bypass graftingâ€. European Journal of Cardio-thoracic Surgery, 2017, 52, 445-453.	0.6	18
94	Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients. American Heart Journal, 2017, 190, 54-63.	1.2	78
95	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Disease. New England Journal of Medicine, 2017, 376, 1087-1089.	13.9	15
96	Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-MainÂDisease. Journal of the American College of Cardiology, 2017, 70, 3113-3122.	1.2	69
97	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. European Heart Journal, 2017, 38, 3124-3134.	1.0	244
98	Approaches to the Role of The Heart Team in Therapeutic Decision Making for Heart Valve Disease. Structural Heart, 2017, 1, 249-255.	0.2	15
99	Standards defining a â€~Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. European Journal of Cardio-thoracic Surgery, 2017, 52, 418-424.	0.6	13
100	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery	1.0	335
101	Staticia) decode anticloss dostructional design of 2002 and 2002 a	0.6	160
102	Effectiveness in a Real-World ObservationÂConfirms Efficacy of Controlled Clinical Trials â^—. Journal of the American College of Cardiology, 2017, 70, 451-452.	1.2	1
103	Standards defining a †Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. European Heart Journal, 2017, 38, 2177-2183.	1.0	83
104	Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial. Structural Heart, 2017, 1, 267-274.	0.2	9
105	Von Willebrand factor multimers during transcatheter aortic valve replacement—an additional clue for detecting post-procedural aortic regurgitation?. Journal of Thoracic Disease, 2016, 8, E1697-E1700.	0.6	1
106	Conceptual model for early health technology assessment of current and novel heart valve interventions. Open Heart, 2016, 3, e000500.	0.9	20
107	Considerations and Recommendations for the Introduction of Objective Performance Criteria for Transcatheter Aortic Heart Valve Device Approval. Circulation, 2016, 133, 2086-2093.	1.6	12
108	The Society of Thoracic Surgeons Clinical Practice Guidelines on Arterial Conduits for Coronary Artery Bypass Grafting. Annals of Thoracic Surgery, 2016, 101, 801-809.	0.7	290

#	Article	IF	CITATIONS
109	Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial. American Heart Journal, 2016, 182, 80-88.	1.2	142
110	Diagnosis and management of aortic valve stenosis in patients with heart failure. European Journal of Heart Failure, 2016, 18, 469-481.	2.9	27
111	EACTS clinical statement: guidance for the provision of adult cardiac surgery: Table 1:. European Journal of Cardio-thoracic Surgery, 2016, 50, 1006-1009.	0.6	27
112	Transcatheter Lotus Valve Implantation inÂa Stenotic Mitral Valve. JACC: Cardiovascular Interventions, 2016, 9, e215-e217.	1.1	5
113	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2223-2235.	13.9	843
114	The Clinical Reality With UncertainÂConsequences of BiologicalÂValve Thrombosis â^—. Journal of the American College of Cardiology, 2016, 68, 2070-2072.	1.2	1
115	Doing better in more complex patients: leading the way for QUIP. European Journal of Cardio-thoracic Surgery, 2016, 49, 397-398.	0.6	5
116	Transcatheter Mitral Valve Implantation in a Patient With an Aortic Mechanical Valve. JACC: Cardiovascular Interventions, 2016, 9, e31-e33.	1.1	1
117	Aortic valve replacement in younger adults: a biological valve is not the logical choice. European Heart Journal, 2016, 37, 2668-2670.	1.0	6
118	Causes of Death Following PCI Versus CABG in Complex CAD. Journal of the American College of Cardiology, 2016, 67, 42-55.	1.2	110
119	Revascularization Options. Heart Failure Clinics, 2016, 12, 135-139.	1.0	12
120	Coronary artery bypass grafting in diabetic patients: do not bypass the pump!. European Journal of Cardio-thoracic Surgery, 2016, 49, 418-419.	0.6	0
121	Coronary artery disease: a dam in the river for ranolazine. Lancet, The, 2016, 387, 100-102.	6.3	1
122	Current decision making and short-term outcome in patients with degenerative aortic stenosis: the Pooled-RotterdAm-Milano-Toulouse In Collaboration Aortic Stenosis survey. EuroIntervention, 2016, 11, e1305-e1313.	1.4	15
123	Five-year haemodynamic outcomes of the first-generation SAPIEN balloon-expandable transcatheter heart valve. EuroIntervention, 2016, 12, 775-782.	1.4	21
124	Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. EuroIntervention, 2016, 12, 861-872.	1.4	61
125	Reply to Hernández-Vaqueroet al European Journal of Cardio-thoracic Surgery, 2015, 48, 177.2-178.	0.6	0
126	The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 597-606.e2.	0.4	18

#	Article	IF	CITATIONS
127	Age Cutoffs for Bioprosthetic vs Mechanical Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2015, 313, 522.	3.8	2
128	Reflect on DEFLECT. European Heart Journal, 2015, 36, 2034-2035.	1.0	1
129	Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. Heart, 2015, 101, 1980-1988.	1.2	15
130	What the cardiothoracic surgeon wants to know from the radiologist: from X-ray reporting to imaging consultancy and Heart Team membership. Pediatric Radiology, 2015, 45, 27-31.	1.1	1
131	Transcatheter Lotus Valve Implantation inÂa Degenerated Carpentier-Edwards Bioprosthesis. JACC: Cardiovascular Interventions, 2015, 8, e27-e28.	1.1	1
132	Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. European Heart Journal, 2015, 36, 1231-1241.	1.0	98
133	Differences in baseline characteristics, practice patterns and clinical outcomes in contemporary coronary artery bypass grafting in the United States and Europe: insights from the SYNTAX randomized trial and registry. European Journal of Cardio-thoracic Surgery, 2015, 47, 685-695.	0.6	26
134	Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization With Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting. Circulation, 2015, 131, 1269-1277.	1.6	167
135	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: PartÂ1: Clinical Trial Design Principles. Journal of the American College of Cardiology, 2015, 66, 278-307.	1.2	191
136	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: PartÂ2: Endpoint Definitions. Journal of the American College of Cardiology, 2015, 66, 308-321.	1.2	413
137	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles. European Heart Journal, 2015, 36, 1851-1877.	1.0	37
138	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions. European Heart Journal, 2015, 36, 1878-1891.	1.0	133
139	Bilateral internal thoracic artery use: will another retrospective study ever strengthen the prospect?. European Journal of Cardio-thoracic Surgery, 2015, 47, 709-711.	0.6	1
140	Incidence and Predictors of Debris Embolizing to the Brain During Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2015, 8, 718-724.	1.1	161
141	Validation of the SYNTAX Revascularization Index to Quantify Reasonable Level of Incomplete Revascularization After Percutaneous Coronary Intervention. American Journal of Cardiology, 2015, 116, 174-186.	0.7	29
142	Smoking Is Associated With Adverse Clinical Outcomes in PatientsÂUndergoing Revascularization With PCI or CABG. Journal of the American College of Cardiology, 2015, 65, 1107-1115.	1.2	99
143	50th Anniversary Landmark Commentary on Carpentier A, Guermonprez JL, Deloche A, Frechette C, DuBost C. The aorta-to-coronary radial artery bypass graft. Ann Thorac Surg 1973;16:111–21. Annals of Thoracic Surgery, 2015, 99, 1500.	0.7	2
144	Methodology manual for European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines. European Journal of Cardio-thoracic Surgery, 2015, 48, ezv309.	0.6	5

#	Article	IF	CITATIONS
145	Aortic valve and aortic diseases: update on current treatment options. Minimally Invasive Therapy and Allied Technologies, 2015, 24, 253-254.	0.6	2
146	Percutaneous coronary invervention versus coronary artery bypass grafting: A meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 831-838.e13.	0.4	33
147	A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genetics in Medicine, 2015, 17, 3-11.	1.1	40
148	Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: An analysis of the SYNTAX Study. Catheterization and Cardiovascular Interventions, 2015, 85, 199-206.	0.7	32
149	CABG, stents, or hybrid procedures for left main disease?. EuroIntervention, 2015, 11, V111-V114.	1.4	10
150	Transcatheter Lotus valve implantation in a regurgitant SAPIEN 3 valve. EuroIntervention, 2015, 11, 356-356.	1.4	6
151	The heart team in acute cardiac care. , 2015, , .		1
152	Measuring risk in valvular interventions: from low risk to futility. EuroIntervention, 2015, 14, W23-W25.	1.4	0
153	Performance of EuroSCORE II in a large US database: implications for transcatheter aortic valve implantation. European Journal of Cardio-thoracic Surgery, 2014, 46, 400-408.	0.6	93
154	Response to Letter Regarding Article, "Quantification of Incomplete Revascularization and Its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: Validation of the Residual SYNTAX Score― Circulation, 2014, 129, e355-6.	1.6	1
155	Cause of death after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2014, 83, E277-82.	0.7	39
156	Role of Percutaneous Coronary Intervention in the Treatment of Left Main Coronary Artery Disease. Seminars in Thoracic and Cardiovascular Surgery, 2014, 26, 187-191.	0.4	1
157	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	0.6	2,164
158	Transapical Versus Transfemoral Aortic Valve Implantation: A Multicenter Collaborative Study. Annals of Thoracic Surgery, 2014, 97, 22-28.	0.7	64
159	Non-cardiac surgery in patients with severe aortic stenosis: time to revise the guidelines?: Figure 1. European Heart Journal, 2014, 35, 2346-2348.	1.0	6
160	The SYNTAX score and its clinical implications. Heart, 2014, 100, 169-177.	1.2	75
161	Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. European Heart Journal, 2014, 35, 2821-2830.	1.0	292
162	Cost, quality, and value in coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2729-2735.e1.	0.4	19

#	Article	IF	CITATIONS
163	Revascularization Options. Cardiology Clinics, 2014, 32, 457-461.	0.9	7
164	Widening clinical applications of the SYNTAX Score. Heart, 2014, 100, 276-287.	1.2	64
165	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	1.0	4,141
166	Cost-Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel or Left Main Coronary Artery Disease. Circulation, 2014, 130, 1146-1157.	1.6	83
167	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ, The, 2014, 348, g3859-g3859.	3.0	291
168	Prediction of Costs and Length of Stay in Coronary Artery Bypass Grafting. Annals of Thoracic Surgery, 2014, 98, 1286-1293.	0.7	59
169	Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial. Circulation, 2014, 129, 2388-2394.	1.6	440
170	Invited Commentary. Annals of Thoracic Surgery, 2014, 97, 528-529.	0.7	0
171	TAVI at institutions without cardiovascular surgery departments: why?. EuroIntervention, 2014, 10, 539-541.	1.4	6
172	Patient selection for TAVI in 2014: is there a justification for treating low- or intermediate-risk patients? The surgeon's view. EuroIntervention, 2014, 10, U11-U15.	1.4	9
173	Surgical or transcatheter mitral valve intervention: complex disease requires complex decisions. EuroIntervention, 2014, 9, 1133-1135.	1.4	9
174	Transcatheter aortic valve replacement and vascular complications definitions. EuroIntervention, 2014, 9, 1317-1322.	1.4	15
175	Multivessel coronary artery disease: quantifying how recent trials should influence clinical practice. Expert Review of Cardiovascular Therapy, 2013, 11, 903-918.	0.6	7
176	Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 737-745.	1.1	54
177	Costs for Surgical Aortic Valve Replacement According to Preoperative Risk Categories. Annals of Thoracic Surgery, 2013, 96, 500-506.	0.7	52
178	CABG or PCI for revascularisation in patients with diabetes?. Lancet Diabetes and Endocrinology,the, 2013, 1, 266-268.	5.5	5
179	Short-Term and Long-Term Clinical Impact of Stent Thrombosis and Graft Occlusion in the SYNTAX Trial at 5 Years. Journal of the American College of Cardiology, 2013, 62, 2360-2369.	1.2	62
180	Coronary artery bypass grafting: Part 2–optimizing outcomes and future prospects. European Heart Journal, 2013, 34, 2873-2886.	1.0	103

#	Article	IF	CITATIONS
181	Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet, The, 2013, 381, 629-638.	6.3	1,490
182	Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 6-23.	0.4	783
183	Paravalvular Leak After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2013, 61, 1125-1136.	1.2	374
184	Analysis of Stroke Occurring in the SYNTAX Trial Comparing Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in the Treatment of Complex Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 344-354.	1.1	46
185	Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation. International Journal of Cardiology, 2013, 168, 5287-5292.	0.8	15
186	Complete Revascularization Is NotÂa Prerequisite for Success in Current Transcatheter Aortic Valve ImplantationÂPractice. JACC: Cardiovascular Interventions, 2013, 6, 867-875.	1.1	105
187	GuÃade práctica clÃnica sobre el tratamiento de las valvulopatÃas (versión 2012). Revista Espanola De Cardiologia, 2013, 66, 131.e1-131.e42.	0.6	2
188	Transcatheter Aortic Valve Replacement in Europe. Journal of the American College of Cardiology, 2013, 62, 210-219.	1.2	199
189	Impact of methodology and assumptions inÂa cost-effectiveness analysis on transcatheter aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 607.	0.4	1
190	Long-Term Survival of Young Patients With Coronary Artery Disease Is Best Realized Through Surgical Revascularization With Mammary Arteries. Journal of the American College of Cardiology, 2013, 61, 2312-2313.	1.2	2
191	A 3-Center Comparison of 1-Year Mortality Outcomes Between Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement on the Basis of Propensity Score Matching Among Intermediate-Risk Surgical Patients. JACC: Cardiovascular Interventions, 2013, 6, 443-451.	1.1	197
192	The Negative Impact of Incomplete Angiographic Revascularization on Clinical Outcomes and Its Association With Total Occlusions. Journal of the American College of Cardiology, 2013, 61, 282-294.	1.2	257
193	Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet, The, 2013, 381, 639-650.	6.3	679
194	A systematic review of risk prediction in adult cardiac surgery: considerations for future model development. European Journal of Cardio-thoracic Surgery, 2013, 43, e121-e129.	0.6	40
195	The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. European Heart Journal, 2013, 34, 2510-2518.	1.0	167
196	Aortic Stenosis in the Elderly. Journal of the American College of Cardiology, 2013, 62, 1002-1012.	1.2	935
197	Coronary artery bypass grafting: Part 1the evolution over the first 50 years. European Heart Journal, 2013, 34, 2862-2872.	1.0	120
198	The new EuroSCORE II does not improve prediction of mortality in high-risk patients undergoing cardiac surgery: a collaborative analysis of two European centres. European Journal of Cardio-thoracic Surgery, 2013, 44, 1006-1011.	0.6	59

#	Article	IF	CITATIONS
199	The European Association for Cardio-Thoracic Surgery (EACTS) database: an introduction. European Journal of Cardio-thoracic Surgery, 2013, 44, e175-e180.	0.6	40
200	Arterial grafting and complete revascularization. Current Opinion in Cardiology, 2013, 28, 646-653.	0.8	5
201	Editorial Comment: The role of EuroSCORE II in 21st century cardiac surgery practice. European Journal of Cardio-thoracic Surgery, 2013, 43, 32-33.	0.6	11
202	Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trialâ€. European Journal of Cardio-thoracic Surgery, 2013, 43, 1006-1013.	0.6	317
203	Single-centre experience with mitral valve repair in asymptomatic patients with severe mitral valve regurgitationâ€. Interactive Cardiovascular and Thoracic Surgery, 2013, 16, 731-737.	0.5	5
204	The bright future of cardiothoracic and vascular surgery: the role of EACTSâ€. European Journal of Cardio-thoracic Surgery, 2013, 43, 211-214.	0.6	3
205	Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score. Circulation, 2013, 128, 141-151.	1.6	326
206	Subgroup Analyses in Trial Reports Comparing Percutaneous Coronary Intervention With Coronary Artery Bypass Surgery. JAMA - Journal of the American Medical Association, 2013, 310, 2097.	3.8	13
207	Minimally invasive transaortic transcatheter aortic valve implantation of the CoreValve prosthesis: the direct aortic approach through a mini-sternotomy. Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery, 2013, 2013, mmt018-mmt018.	0.5	3
208	The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy. EuroIntervention, 2013, 8, 1277-1285.	1.4	71
209	The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy. EuroIntervention, 2013, 9, 1009-1010.	1.4	15
210	Cost-effectiveness of transcatheter valvular interventions: economic challenges. EuroIntervention, 2013, 9, S48-S54.	1.4	21
211	Failing surgical bioprosthesis in aortic and mitral position. EuroIntervention, 2013, 9, S77-S83.	1.4	5
212	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus documentâ€. European Heart Journal, 2012, 33, 2403-2418.	1.0	900
213	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). European Journal of Cardio-thoracic Surgery, 2012, 42, S45-S60.	0.6	1,605
214	EACTS guidelines for the use of patient safety checklists. European Journal of Cardio-thoracic Surgery, 2012, 41, 993-1004.	0.6	33
215	Preoperative and operative predictors of delirium after cardiac surgery in elderly patients. European Journal of Cardio-thoracic Surgery, 2012, 41, 544-549.	0.6	127
216	Towards excellence in revascularization for left main coronary artery disease. Current Opinion in Cardiology, 2012, 27, 604-610.	0.8	3

#	Article	IF	CITATIONS
217	ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. European Heart Journal, 2012, 33, 822-828.	1.0	152
218	Off-Pump or On-Pump Coronary-Artery Bypass Grafting. New England Journal of Medicine, 2012, 367, 577-578.	13.9	12
219	Patient selection for transcatheter aortic valve replacement: what does the future hold?. Expert Review of Cardiovascular Therapy, 2012, 10, 679-681.	0.6	8
220	The impact of prosthesis–patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. European Heart Journal, 2012, 33, 1518-1529.	1.0	410
221	Letter by Van de Werf et al Regarding Article, "Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians― Stroke, 2012, 43, e46-7; author reply e49.	1.0	Ο
222	Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) trial. European Heart Journal, 2012, 33, 3105-3113.	1.0	119
223	What do we know about the natural history of severe symptomatic aortic valve stenosis?. Interventional Cardiology, 2012, 4, 203-210.	0.0	Ο
224	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2012, 59, 1200-1254.	1.2	706
225	Persistent Annual Permanent Pacemaker Implantation Rate After Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis. Annals of Thoracic Surgery, 2012, 94, 1143-1149.	0.7	53
226	Costs of Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients. Annals of Thoracic Surgery, 2012, 94, 1954-1960.	0.7	94
227	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, e29-e84.	0.4	107
228	Guidelines on the management of valvular heart disease (version 2012). European Heart Journal, 2012, 33, 2451-2496.	1.0	3,465
229	Guidelines on the management of valvular heart disease (version 2012). European Journal of Cardio-thoracic Surgery, 2012, 42, S1-S44.	0.6	1,313
230	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dablGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). American Heart Journal, 2012, 163, 931-937.e1.	1.2	164
231	Drug-eluting stent implantation for coronary artery disease: current stents and a comparison with bypass surgery. Current Opinion in Pharmacology, 2012, 12, 147-154.	1.7	4
232	Transcatheter aortic valve implantation: 10-year anniversary. Part II: clinical implications. European Heart Journal, 2012, 33, 2399-2402.	1.0	51
233	Non-inferiority study design: lessons to be learned from cardiovascular trials. European Heart Journal, 2012, 33, 1318-1324.	1.0	126
234	Predicting prognosis in cardiac surgery: a prophecy?. European Journal of Cardio-thoracic Surgery, 2012, 41, 732-733.	0.6	14

#	Article	IF	CITATIONS
235	Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications. European Heart Journal, 2012, 33, 2388-2398.	1.0	125
236	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. European Heart Journal, 2012, 33, 3098-3104.	1.0	138
237	Appropriate Coronary Artery Bypass Grafting Use in the Percutaneous Coronary Intervention Era: Are We Finally Making Progress?. Seminars in Thoracic and Cardiovascular Surgery, 2012, 24, 241-243.	0.4	3
238	Clinical Outcomes After Transcatheter Aortic Valve Replacement Using Valve Academic Research Consortium Definitions. Journal of the American College of Cardiology, 2012, 59, 2317-2326.	1.2	517
239	Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2012, 60, 1438-1454.	1.2	1,560
240	Risk Profile and 3-Year Outcomes From the SYNTAX Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting Nested Registries. JACC: Cardiovascular Interventions, 2012, 5, 618-625.	1.1	82
241	A Global Risk Approach to Identify Patients With Left Main or 3-Vessel Disease Who Could Safely and Efficaciously Be Treated With Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 606-617.	1.1	91
242	Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. European Journal of Cardio-thoracic Surgery, 2012, 41, 535-541.	0.6	182
243	Do Differences in Repeat Revascularization Explain the Antianginal Benefits of Bypass Surgery Versus Percutaneous Coronary Intervention?. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 267-275.	0.9	28
244	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. Catheterization and Cardiovascular Interventions, 2012, 79, 1023-1082.	0.7	46
245	Invited Commentary. Annals of Thoracic Surgery, 2012, 93, 530.	0.7	0
246	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. Annals of Thoracic Surgery, 2012, 93, 1340-1395.	0.7	62
247	Economic outcomes of percutaneous coronary intervention with drugâ€eluting stents versus bypass surgery for patients with left main or threeâ€vessel coronary artery disease: Oneâ€year results from the SYNTAX trial. Catheterization and Cardiovascular Interventions, 2012, 79, 198-209.	0.7	48
248	Completely percutaneous transcatheter aortic valve implantation through transaxillary route: an evolving concept. EuroIntervention, 2012, 7, 1340-1342.	1.4	15
249	The SURTAVI model: proposal for a pragmatic risk stratification for patients with severe aortic stenosis. EuroIntervention, 2012, 8, 258-266.	1.4	52
250	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document#. EuroIntervention, 2012, 8, 782-795.	1.4	182
251	Determinants of long-term outcome following bypass surgery ., 2012, , 422-427.		0
252	Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials. Journal of the American College of Cardiology, 2011, 57, 253-269.	1.2	735

#	Article	IF	CITATIONS
253	Nonrandomized Data on Drug-Eluting Stents Compared With Coronary Bypass Surgery. Journal of the American College of Cardiology, 2011, 57, 2457-2458.	1.2	1
254	Current concepts on coronary revascularization in diabetic patients. European Heart Journal, 2011, 32, 2748-2757.	1.0	82
255	Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. European Heart Journal, 2011, 32, 2125-2134.	1.0	506
256	A crucial factor in shared decision making: the team approach. Lancet, The, 2011, 377, 1836.	6.3	35
257	Surgery in current therapy for infective endocarditis. Vascular Health and Risk Management, 2011, 7, 255.	1.0	26
258	Complex coronary anatomy in coronary artery bypass graft surgery: Impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 130-140.	0.4	124
259	Methodologic issues regarding background mortality in observational studies. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1289-1290.	0.4	2
260	Effect of Experience on Results of Transcatheter Aortic Valve Implantation Using a Medtronic CoreValve System. American Journal of Cardiology, 2011, 107, 1824-1829.	0.7	57
261	Bypass Versus Drug-Eluting Stents at Three Years in SYNTAX Patients With Diabetes Mellitus or Metabolic Syndrome. Annals of Thoracic Surgery, 2011, 92, 2140-2146.	0.7	84
262	Inâ€hospital complications after transcatheter aortic valve implantation revisited according to the valve academic research consortium definitions. Catheterization and Cardiovascular Interventions, 2011, 78, 457-467.	0.7	55
263	Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. European Heart Journal, 2011, 32, 205-217.	1.0	719
264	Carriage of Reduced-Function <i>CYP2C19</i> Allele Among Patients Treated With Clopidogrel. JAMA - Journal of the American Medical Association, 2011, 305, 467.	3.8	4
265	The 4th European Association for Cardio-Thoracic Surgery adult cardiac surgery database report. Interactive Cardiovascular and Thoracic Surgery, 2011, 12, 4-5.	0.5	42
266	Quality of Life after PCI with Drug-Eluting Stents or Coronary-Artery Bypass Surgery. New England Journal of Medicine, 2011, 364, 1016-1026.	13.9	242
267	Details in a meta-analysis comparing mitral valve repair to replacement for ischemic regurgitation. European Journal of Cardio-thoracic Surgery, 2011, 41, 236-7; author reply 237-8.	0.6	2
268	New Anticoagulants in Cardiac Surgery. Interventional Cardiology Review, 2011, 6, 71.	0.7	5
269	Adoption of Transcatheter Aortic Valve Implantation in Western Europe. Interventional Cardiology Review, 2011, 9, 37.	0.7	9
270	Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS). EuroIntervention, 2011, 7, 670-679.	1.4	36

#	Article	IF	CITATIONS
271	What is the evidence allowing us to state that transcatheter aortic valve replacement via the femoral artery is a more attractive option compared to transapical valve replacement?. EuroIntervention, 2011, 7, 903-904.	1.4	9
272	Bilateral mammary artery vs. single mammary artery grafting: promising early results: but will the match finish with enough players?. European Heart Journal, 2010, 31, 2444-2446.	1.0	24
273	Two cases of aneurysm of the anterior mitral valve leaflet associated with transcatheter aortic valve endocarditis: A mere coincidence?. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, e36-e38.	0.4	26
274	Prosthesis–Patient Mismatch After Transcatheter Aortic Valve Implantation With the Medtronic CoreValve System in Patients With Aortic Stenosis. American Journal of Cardiology, 2010, 106, 255-260.	0.7	61
275	Validation of a prognostic model to predict survival after non-small-cell lung cancer surgery. European Journal of Cardio-thoracic Surgery, 2010, 38, 615-619.	0.6	12
276	Editorial commentls there enough evidence that proves clinical equipoise between stenting and coronary surgery for patients with left main coronary artery disease?. European Journal of Cardio-thoracic Surgery, 2010, 38, 428-430.	0.6	8
277	Diabetic and Nondiabetic Patients With Left Main and/or 3-Vessel Coronary Artery Disease. Journal of the American College of Cardiology, 2010, 55, 1067-1075.	1.2	271
278	Long term follow up after surgery in congenitally corrected transposition of the great arteries with a right ventricle in the systemic circulation. Journal of Cardiothoracic Surgery, 2010, 5, 74.	0.4	37
279	Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving System—A Bern-Rotterdam Study. American Heart Journal, 2010, 159, 323-329.	1.2	149
280	Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial. Circulation, 2010, 121, 2645-2653.	1.6	561
281	Cost effectiveness of coronary revascularisation. EuroIntervention, 2010, 5, 763-767.	1.4	6
282	Transcatheter aortic valve implantation after PARTNER: what is up next?. EuroIntervention, 2010, 6, 560-561.	1.4	4
283	Left main stenting: do we need another study?. EuroIntervention, 2010, 6, J118-J122.	1.4	1
284	Transapical implantation of a self-expanding aortic valve bioprosthesis — animal feasibility studyâ~†. European Journal of Cardio-thoracic Surgery, 2009, 36, 813-817.	0.6	3
285	How to assess risks of valve surgery: quality, implementation and future of risk models. Heart, 2009, 95, 1958-1963.	1.2	10
286	Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: Weighing lifetime anticoagulant-related event risk against reoperation risk. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 881-886.e5.	0.4	156
287	Intraoperative Real Time Threeâ€Dimensional Transesophageal Echocardiographic Measurement of Hemodynamic, Anatomic and Functional Changes after Aortic Valve Replacement. Echocardiography, 2009, 26, 96-99.	0.3	13
288	Complexity of Coronary Vasculature Predicts Outcome of Surgery for Left Main Disease. Annals of Thoracic Surgery, 2009, 87, 1097-1105.	0.7	36

#	Article	IF	CITATIONS
289	Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. New England Journal of Medicine, 2009, 360, 961-972.	13.9	3,634
290	Therapeutic decisions for patients with symptomatic severe aortic stenosis: room for improvement?. European Journal of Cardio-thoracic Surgery, 2009, 35, 953-957.	0.6	49
291	Four-Year Outcome of OPCAB No-Touch With Total Arterial Y-Graft: Making the Best Treatment a Daily Practice. Annals of Thoracic Surgery, 2009, 88, 796-801.	0.7	50
292	Surgical Treatment of Active Native Aortic Valve Endocarditis With Allografts and Mechanical Prostheses. Annals of Thoracic Surgery, 2009, 88, 1814-1821.	0.7	80
293	Clinical endpoints in transcatheter aortic valve implantation: a call to ARC for standardised definitions. EuroIntervention, 2009, 5, 29-31.	1.4	11
294	Assessment of the SYNTAX score in the Syntax study. EuroIntervention, 2009, 5, 50-56.	1.4	480
295	A comparison of patient characteristics and 30-day mortality outcomes after transcatheter aortic valve implantation and surgical aortic valve replacement for the treatment of aortic stenosis: a two-centre study. EuroIntervention, 2009, 5, 580-588.	1.4	54
296	Do We Need Separate Risk Stratification Models for Hospital Mortality After Heart Valve Surgery?. Annals of Thoracic Surgery, 2008, 85, 921-930.	0.7	56
297	Invited Commentary. Annals of Thoracic Surgery, 2008, 86, 219.	0.7	0
298	Three life-years gained from smoking cessation after coronary artery bypass surgery: A 30-year follow-up study. American Heart Journal, 2008, 156, 473-476.	1.2	53
299	The clinical outcome after coronary bypass surgery: a 30-year follow-up study. European Heart Journal, 2008, 30, 453-458.	1.0	68
300	Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX studyâ~†. European Journal of Cardio-thoracic Surgery, 2008, 34, 376-383.	0.6	16
301	Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Furopean Heart Journal, 2008, 29, 1463-1470.	1.0	656
302	Management of elderly patients with aortic valve disease. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 600-601.	3.3	1
303	Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European lournal of Cardio-thoracic Surgery. 2008. 34. 1-8.	0.6	217
304	Optimum management of elderly patients with calcified aortic stenosis. Expert Review of Cardiovascular Therapy, 2008, 6, 491-501.	0.6	3
305	Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention. 2008. 4. 193-199.	1.4	134
306	Population characteristics, treatment assignment and survival of patients with aortic stenosis referred for percutaneous valve replacement. EuroIntervention, 2008, 4, 250-255.	1.4	45

#	Article	IF	CITATIONS
307	How should I treat a patient with severe and symptomatic aortic stenosis who is rejected for surgical and transfemoral valve replacement and in whom a transapical implantation was aborted?. EuroIntervention, 2008, 4, 292-296.	1.4	3
308	Early echocardiographic evaluation following percutaneous implantation with the self-expanding CoreValve ReValving System aortic valve bioprosthesis. EuroIntervention, 2008, 4, 351-357.	1.4	54
309	Long-term follow-up and quality of life after closure of ventricular septal defect in adults. European Journal of Cardio-thoracic Surgery, 2007, 32, 215-219.	0.6	34
310	Adapt or die. The imperative for a culture of innovation in cardio-thoracic surgical training. European Journal of Cardio-thoracic Surgery, 2007, 31, 959-959.	0.6	6
311	Allografts for aortic valve or root replacement: insights from an 18-year single-center prospective follow-up studyâ~†. European Journal of Cardio-thoracic Surgery, 2007, 31, 851-859.	0.6	46
312	Virtual reality 3D echocardiography in the assessment of tricuspid valve function after surgical closure of ventricular septal defect. Cardiovascular Ultrasound, 2007, 5, 8.	0.5	14
313	Cyphering the Complexity of Coronary Artery Disease Using the Syntax Score to Predict Clinical Outcome in Patients With Three-Vessel Lumen Obstruction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 99, 1072-1081.	0.7	269
314	Usefulness of microsimulation to translate valve performance into patient outcome: Patient prognosis after aortic valve replacement with the Carpentier–Edwards supra-annular valve. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 702-709.e1.	0.4	12
315	Predicted patient outcome after aortic valve replacement with Medtronic Stentless Freestyle bioprostheses. Journal of Heart Valve Disease, 2007, 16, 423-8; discussion 429.	0.5	8
316	True percutaneous implantation of the CoreValve aortic valve prosthesis by the combined use of ultrasound guided vascular access, Prostar(R) XL and the TandemHeart(R). EuroIntervention, 2007, 2, 500-5.	1.4	37
317	Emergency Surgery Due to Haematoma in a Case of Left Atrial Myxoma. Heart Lung and Circulation, 2006, 15, 191-193.	0.2	0
318	The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. American Heart Journal, 2006, 151, 1194-1204.	1.2	281
319	Long-term survival after non–small cell lung cancer surgery: Development and validation of a prognostic model with a preoperative and postoperative mode. Journal of Thoracic and Cardiovascular Surgery, 2006, 132, 491-498.	0.4	63
320	Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease.â~†Insights from the SYNTAX run-in phase. European Journal of Cardio-thoracic Surgery, 2006, 29, 486-491.	0.6	181
321	Does the type of biological valve affect patient outcome?. Interactive Cardiovascular and Thoracic Surgery, 2006, 5, 398-402.	0.5	9
322	Outcome after aortic valve replacement in young adults: is patient profile more important than prosthesis type?. Journal of Heart Valve Disease, 2006, 15, 479-87; discussion 487.	0.5	12
323	Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. European Journal of Cardio-thoracic Surgery, 2005, 28, 759-762.	0.6	207
324	Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease. Circulation, 2005, 111, 1383-1389.	1.6	305

#	Article	IF	CITATIONS
325	Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer. Annals of Thoracic Surgery, 2005, 79, 375-382.	0.7	255
326	Survival After Pathological Stage IA Nonsmall Cell Lung Cancer: Tumor Size Matters. Annals of Thoracic Surgery, 2005, 79, 1137-1141.	0.7	64
327	Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer. Annals of Thoracic Surgery, 2005, 80, 1021-1026.	0.7	38
328	Pediatric Autograft Aortic Root Replacement: A Prospective Follow-Up Study. Annals of Thoracic Surgery, 2005, 80, 1628-1633.	0.7	34
329	The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention, 2005, 1, 219-27.	1.4	1,349
330	Is a bicuspid aortic valve a risk factor for adverse outcome after an autograft procedure?. Annals of Thoracic Surgery, 2004, 77, 1998-2003.	0.7	9
331	Long-term follow-up of coronary artery bypass grafting in three-vessel disease using exclusively pedicled bilateral internal thoracic and right gastroepiploic arteries. Annals of Thoracic Surgery, 2004, 77, 794-799.	0.7	68
332	Lung resection for non–small-cell lung cancer in patients older than 70: mortality, morbidity, and late survival compared with the general population. Annals of Thoracic Surgery, 2003, 76, 1796-1801.	0.7	109
333	Factors associated with perioperative complications and long-term results after pulmonary resection for primary carcinoma of the lung. European Journal of Cardio-thoracic Surgery, 2003, 23, 26-29.	0.6	47
334	Value of Keeping Records of Mortality. The European Journal of Surgery, 2002, 168, 436-440.	1.0	3
335	Echocardiographic Imaging of Stentless Aortic Valve Prostheses. Echocardiography, 2000, 17, 625-629.	0.3	1
336	Stentless bioprostheses have ideal haemodynamics, even in the small aortic root. International Journal of Cardiovascular Imaging, 2000, 16, 359-364.	0.2	6
337	Brom's three-patch technique for repair of supravalvular aortic stenosis. Journal of Thoracic and Cardiovascular Surgery, 1999, 118, 252-258.	0.4	67
338	Survival of proximal third gastric carcinoma. , 1998, 68, 183-186.		8

Survival of proximal third gastric carcinoma. , 1998, 68, 183-186. 338